Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

AAM said the law sets up a process under which a drug would have price controls applied before a generic or biosimilar even ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

As per provisional closing data, the barometer index, the S&P BSE Sensex, advanced 147.71 points or 0.20% to 74,602.12. The Nifty 50 index fell 5.80 points or 0.03% to 22,547.55.

The domestic equity benchmarks closed near flat line on Tuesday, with investors cautiously awaiting key US economic data, including Core PCE and GDP figures, impacting Federal Reserve policy ...